Bulletin of the World Health Organization

Use of data from registered clinical trials to identify gaps in health research and development

Roderik F Viergever, Robert F Terry & Ghassan Karam

Volume 91, Number 6, June 2013, 416-425C

Table 2. The health problems being investigated in the actively recruiting, interventional trials registered on the International Clinical Trials Registry Platform (ICTRP), 2012

Health condition or problem No. of trials in samplea Estimate and (95% CI)
Percentage of trials in ICTRPb No. of trials in ICTRP
Total Per 1 000 000 DALYs
Communicable, maternal, perinatal and nutritional 222 10.1 (8.9–11.4) 4440 (3916–5025) 7.4 (6.5–8.3)
Infectious and parasitic diseases 132 6.0 (5.1–7.1) 2640 (2236–3111) 8.7 (7.4–10.3)
    Tuberculosis 11 0.5 (0.3–0.9) 220 (123–393) 6.4 (3.6–11.5)
    HIV/AIDS 32 1.5 (1.0–2.1) 640 (454–900) 10.9 (7.8–15.4)
    Diarrhoeal diseases 10 0.5 (0.2–0.8) 200 (109–367) 2.7 (1.5–5.0)
    Childhood cluster diseases 6 0.3 (0.1–0.6) 120 (55–261) 4.0 (1.8–8.6)
        Poliomyelitisc 1 0.0 (0.0–0.3) 20 (4–113)  –
        Diphtheria 1 0.0 (0.0–0.3) 20 (4–113) 115.2 (20.3–651.6)
        Measles 2 0.1 (0.0–0.3) 40 (11–146) 2.7 (0.7–9.8)
        Tetanus 2 0.1 (0.0–0.3) 40 (11–146) 7.6 (2.1–27.6)
    Meningitis 3 0.1 (0.0–0.4) 60 (20–176) 5.3 (1.8–15.4)
    Hepatitis B 8 0.4 (0.2–0.7) 160 (81–315) 77.4 (39.2–152.4)
    Hepatitis C 16 0.7 (0.4–1.2) 320 (197–518) 335.2 (206.6–543.0)
    Malaria 9 0.4 (0.2–0.8) 180 (95–341) 5.3 (2.8–10.0)
    Leprosy 2 0.1 (0.0–0.3) 40 (11–146) 206.4 (56.6–751.2)
    Dengue 2 0.1 (0.0–0.3) 40 (11–146) 59.7 (16.4–217.4)
    Intestinal nematode infections 1 0.0 (0.0–0.3) 20 (4–113) 5.0 (0.9–28.2)
        Ascariasis 1 0.0 (0.0–0.3) 20 (4–113) 10.8 (1.9–61.1)
    Other infectious diseasec 32 1.5 (1.0–2.1) 640 (454–900)  –
Respiratory infections 26 1.2 (0.8–1.7) 520 (355–759) 5.3 (3.6–7.8)
    Lower respiratory infections 16 0.7 (0.4–1.2) 320 (197–518) 3.4 (2.1–5.5)
    Upper respiratory infections 9 0.4 (0.2–0.8) 180 (95–341) 100.7 (53.0–191.0)
    Otitis media 1 0.0 (0.0–0.3) 20 (4–113) 13.4 (2.4–76.0)
Maternal conditions 36 1.6 (1.2–2.3) 720 (521–993) 18.5 (13.4–25.5)
    Maternal haemorrhage 1 0.0 (0.0–0.3) 20 (4–113) 4.5 (0.8–25.5)
    Hypertensive disorders of pregnancy 5 0.2 (0.1–0.5) 100 (43–234) 53.0 (22.6–123.7)
    Obstructed labour 6 0.3 (0.1–0.6) 120 (55–261) 41.6 (19.1–90.6)
    Abortion 5 0.2 (0.1–0.5) 100 (43–234) 13.5 (5.8–31.5)
    Otherc 19 0.9 (0.6–1.3) 380 (244–592)  –
Conditions arising during perinatal period 20 0.9 (0.6–1.4) 400 (259–616) 3.2 (2.1–4.9)
    Low birth weight 13 0.6 (0.3–1.0) 260 (152–444) 5.9 (3.4–10.0)
    Birth asphyxia and birth trauma 2 0.1 (0.0–0.3) 40 (11–146) 1.0 (0.3–3.5)
    Neonatal infections and other conditionsc 5 0.2 (0.1–0.5) 100 (43–234)  –
Nutritional deficiencies 8 0.4 (0.2–0.7) 160 (81–315) 4.1 (2.1–8.1)
    Protein-energy malnutrition 1 0.0 (0.0–0.3) 20 (4–113) 1.1 (0.2–6.5)
    Iron-deficiency anaemia 4 0.2 (0.1–0.5) 80 (31–205) 5.0 (1.9–12.7)
    Otherc
3
0.1 (0.0–0.4)
60 (20–176)
 –
Non-communicable 1917 87.3 (85.9–88.7) 38 340 (37 700–38 922) 52.4 (51.5–53.2)
Malignant neoplasms 667 30.4 (28.5–32.3) 13 340 (12 511–14 199) 171.4 (160.8–182.5)
    Mouth and oropharynx cancers 19 0.9 (0.6–1.4) 385 (248–598) 101.7 (65.4–157.9)
    Oesophagus cancer 11 0.5 (0.3–0.9) 214 (119–385) 44.9 (24.9–80.8)
    Stomach cancer 34 1.6 (1.1–2.2) 685 (492–953) 91.5 (65.7–127.2)
    Colon and rectum cancers 44 2.0 (1.5–2.7) 878 (655–1174) 149.5 (111.6–199.9)
    Liver cancer 33 1.5 (1.1–2.1) 664 (474–928) 98.9 (70.6–138.3)
    Pancreatic cancer 25 1.1 (0.8–1.7) 492 (333–727) 221.9 (150.1–327.5)
    Trachea, bronchus and lung cancers 80 3.7 (3.0–4.5) 1606 (1295–1988) 136.5 (110.1–168.9)
    Melanoma and other skin cancers 12 0.5 (0.3–0.9) 236 (134–413) 333.5 (190.0–584.5)
    Breast cancer 94 4.3 (3.5–5.2) 1884 (1546–2293) 284.3 (233.2–345.9)
    Cervix uteri cancer 14 0.6 (0.4–1.1) 278 (166–467) 74.8 (44.6–125.5)
    Corpus uteri cancer 6 0.3 (0.1–0.6) 128 (60–273) 172.5 (81.1–366.3)
    Ovary cancer 16 0.7 (0.5–1.2) 321 (198–520) 184.1 (113.5–297.9)
    Prostate cancer 35 1.6 (1.2–2.2) 707 (510–978) 383.4 (276.7–530.5)
    Bladder cancer 11 0.5 (0.3–0.9) 214 (119–385) 147.6 (81.8–265.6)
    Lymphomas and multiple myeloma 73 3.3 (2.6–4.2) 1456 (1161–1822) 339.8 (271.1–425.3)
    Leukaemia 77 3.5 (2.8–4.4) 1542 (1238–1917) 311.9 (250.4–387.8)
    Otherc 82 3.8 (3.0–4.6) 1649 (1334–2035)  –
Other neoplasmsc 25 1.1 (0.8–1.7) 500 (339–736)  –
Diabetes mellitus 85 3.9 (3.1–4.8) 1700 (1380–2091) 86.3 (70.0–106.1)
Endocrine disordersc 122 5.6 (4.7–6.6) 2440 (2052–2896)
Neuropsychiatric conditions 282 12.8 (11.5–14.3) 5640 (5054–6283) 28.3 (25.4–31.5)
    Unipolar depressive disorders 28 1.3 (0.9–1.8) 560 (388–807) 8.6 (5.9–12.3)
    Bipolar affective disorder 8 0.4 (0.2–0.7) 160 (81–315) 11.1 (5.6–21.8)
    Schizophrenia 26 1.2 (0.8–1.7) 520 (355–759) 31.0 (21.2–45.3)
    Epilepsy 11 0.5 (0.3–0.9) 220 (123–393) 28.0 (15.7–50.0)
    Alcohol use disorders 9 0.4 (0.2–0.8) 180 (95–341) 7.6 (4.0–14.4)
    Alzheimer and other dementias 18 0.8 (0.5–1.3) 360 (228–567) 32.3 (20.4–50.9)
    Parkinson disease 11 0.5 (0.3–0.9) 220 (123–393) 128.6 (71.9–229.8)
    Multiple sclerosis 18 0.8 (0.5–1.3) 360 (228–567) 235.7 (149.3–371.6)
    Drug use disorders 16 0.7 (0.4–1.2) 320 (197–518) 38.2 (23.6–61.9)
    Post-traumatic stress disorder 9 0.4 (0.2–0.8) 180 (95–341) 51.9 (27.3–98.4)
    Obsessive–compulsive disorder 5 0.2 (0.1–0.5) 100 (43–234) 19.6 (8.4–45.8)
    Panic disorder 1 0.0 (0.0–0.3) 20 (4–113) 2.9 (0.5–16.2)
    Insomnia (primary) 5 0.2 (0.1–0.5) 100 (43–234) 27.6 (11.8–64.5)
    Migraine 6 0.3 (0.1–0.6) 120 (55–261) 15.5 (7.1–33.6)
    Otherc 111 5.1 (4.2–6.1) 2220 (1851–2658) – 
Sense organ diseases 73 3.3 (2.7–4.2) 1460 (1165–1827) 16.8 (13.4–21.0)
    Glaucoma 12 0.5 (0.3–1.0) 240 (137–418) 50.8 (29.1–88.5)
    Cataracts 6 0.3 (0.1–0.6) 120 (55–261) 6.8 (3.1–14.7)
    Refractive errors 4 0.2 (0.1–0.5) 80 (31–205) 2.9 (1.1–7.4)
    Hearing loss (adult onset) 1 0.0 (0.0–0.3) 20 (4–113) 0.7 (0.1–4.1)
    Macular degeneration and other 50 2.3 (1.7–3.0) 1000 (760–1313) 107.6 (81.8–141.2)
Cardiovascular diseases 219 10.0 (8.8–11.3) 4380 (3860–4961) 28.9 (25.5–32.8)
    Rheumatic heart disease 5 0.2 (0.1–0.5) 100 (43–234) 19.3 (8.2–45.0)
    Hypertensive heart disease 28 1.3 (0.9–1.8) 560 (388–807) 69.8 (48.4–100.6)
    Ischaemic heart disease 70 3.2 (2.5–4.0) 1400 (1111–1760) 22.4 (17.8–28.1)
    Cerebrovascular disease 40 1.8 (1.3–2.5) 800 (589–1085) 17.2 (12.6–23.3)
    Inflammatory heart disease 2 0.1 (0.0–0.3) 40 (11–146) 6.4 (1.8–23.3)
    Otherc 74 3.4 (2.7–4.2) 1480 (1183–1849) – 
Respiratory diseases 75 3.4 (2.7–4.3) 1500 (1200–1871) 25.4 (20.3–31.7)
    Chronic obstructive pulmonary disease 24 1.1 (0.7–1.6) 480 (323–712) 15.9 (10.7–23.6)
    Asthma 26 1.2 (0.8–1.7) 520 (355–759) 31.9 (21.8–46.5)
    Otherc 25 1.1 (0.8–1.7) 500 (339–736) – 
Digestive diseases 77 3.5 (2.8–4.4) 1540 (1236–1915) 36.2 (29.1–45.1)
    Peptic ulcer disease 4 0.2 (0.1–0.5) 80 (31–205) 16.1 (6.3–41.4)
    Cirrhosis of the liver 10 0.5 (0.2–0.8) 200 (109–367) 14.7 (8.0–26.9)
    Appendicitis 1 0.0 (0.0–0.3) 20 (4–113) 47.8 (8.4–270.4)
    Otherc 62 2.8 (2.2–3.6) 1240 (970–1582) – 
Genitourinary diseases 84 3.8 (3.1–4.7) 1680 (1362–2069) 113.9 (92.3–140.2)
    Nephritis and nephrosis 30 1.4 (1.0–1.9) 600 (421–854) 66.2 (46.5–94.2)
    Benign prostatic hypertrophy 3 0.1 (0.0–0.4) 60 (20–176) 22.5 (7.7–66.1)
    Otherc 51 2.3 (1.8–3.0) 1020 (778–1335)  –
Skin diseasesc 49 2.2 (1.7–2.9) 980 (743–1290)  –
Musculoskeletal disorders 124 5.6 (4.8–6.7) 2480 (2089–2939) 80.3 (67.7–95.2)
    Rheumatoid arthritis 20 0.9 (0.6–1.4) 400 (259–616) 79.2 (51.3–122.0)
    Osteoarthritis 27 1.2 (0.8–1.8) 540 (372–783) 34.6 (23.9–50.2)
    Goutc 1 0.0 (0.0–0.3) 20 (4–113)
    Low back painc 9 0.4 (0.2–0.8) 180 (95–341)
    Otherc 67 3.1 (2.4–3.9) 1340 (1058–1694)
Congenital anomaliesc 18 0.8 (0.5–1.3) 360 (228–567)
    Down syndrome 2 0.1 (0.0–0.3) 40 (11–146)
    Congenital heart anomalies 2 0.1 (0.0–0.3) 40 (11–146)
    Other 14 0.6 (0.4–1.1) 280 (167–469)
Oral conditionsc 17 0.8 (0.5–1.2) 340 (213–543)
    Dental caries 2 0.1 (0.0–0.3) 40 (11–146) – 
    Periodontal disease 1 0.0 (0.0–0.3) 20 (4–113) – 
    Edentulism 3 0.1 (0.0–0.4) 60 (20–176) – 
    Other
11
0.5 (0.3–0.9)
220 (123–393)
 –
Injuriesc 56 2.6 (2.0–3.3) 1120 (865–1448) 6.0 (4.6–7.7)

CI, confidence interval; DALY, disability-adjusted life year; HIV/AIDS, human immunodeficiency virus/acquired immunodeficiency syndrome.

a Estimated percentages and numbers for the whole ICTRP were based on the results of the analysis of the records for a 5% sample of the trials registered on the platform. Health conditions or problems for which no trials were found in the sample were excluded from this table.

b The percentages shown are those of the 2195 trials in the sample for which the health condition or problem studied could be classified. The condition or problem investigated in the other 186 trials included in the sample could not be classified because there was insufficient information in the registered records of the trial or because the trials included participants with many different diseases.

c Burden-of-disease data for this condition or problem were either not available or excluded from this table for the reasons given in the methods section.